NDAVAGINALSUPPOSITORY
Approved
Aug 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
6/8 — Strong
CLEOCIN (clindamycin phosphate) by Pfizer is clinical pharmacology mechanism of action clindamycin is an antibacterial drug (see). Approved for acne vulgaris, bacterial vaginosis. First approved in 1999.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CLEOCIN (clindamycin phosphate) is a lincosamide antibiotic administered as a vaginal suppository for treating bacterial vaginosis and acne vulgaris. It works by inhibiting bacterial protein synthesis, with only 30% systemic absorption due to its local vaginal delivery, resulting in substantially lower systemic exposure compared to oral or parenteral formulations.
$0.166MPart D
LOE ApproachingDeclining
Product is in late-stage lifecycle with minimal Part D spending; expect lean team structure and focus on market defense rather than expansion.
Mechanism of Action
CLINICAL PHARMACOLOGY Mechanism of Action Clindamycin is an antibacterial drug (See). Pharmacokinetics Systemic absorption of clindamycin was estimated following a once-a-day intravaginal dose of one clindamycin phosphate vaginal suppository (equivalent to 100 mg clindamycin) administered to 11…
Indications (2)
Worked on CLEOCIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.